Standing orders let a nurse practitioner or aesthetician administer semaglutide, tirzepatide, or Zepbound under a physician's pre-approved protocol instead of waiting on a signature for every patient — and getting the document wrong is the fastest way to fail a state board audit in 2026.
- Standing orders for weight loss injectables must be signed by a supervising physician and reviewed at least annually to stay compliant in 2026.
- A vague dosing range or missing exclusion criteria is the top reason boards flag semaglutide and tirzepatide protocols.
- US Medical Directors builds and reviews standing order templates as part of ongoing collaborating physician and chart review services.
- Skip generic templates pulled from forums — state-specific language on supervision ratios and telehealth rules changes yearly.
Why this matters
Weight loss injectable programs are the fastest-growing service line at most medspas right now, and they carry more regulatory exposure than Botox or filler because dosing is titrated over weeks and contraindications (pancreatitis history, thyroid cancer family history, pregnancy) actually kill patients if missed.
A standing order isn't a formality — it's the legal document that lets your NP or RN act within a physician's license instead of practicing medicine independently. States audit these programs specifically because tirzepatide and semaglutide volume exploded between 2023 and 2026, and boards have caught up on enforcement.
Get the standing order wrong — outdated dosing tiers, no renewal date, no collaborating physician signature — and every injection given under it becomes a liability question, not just a paperwork gap.
What you'll need
- A signed collaborating physician or medical director agreement covering weight loss services specifically, not a generic aesthetics contract
- Your state's current nurse practice act or PA supervision rules for weight loss/GLP-1 prescribing
- A dosing protocol from the drug manufacturer or your compounding pharmacy (starting dose, titration schedule, max dose)
- A patient intake and exclusion criteria checklist (pregnancy, MEN2 history, active pancreatitis, gastroparesis)
- A good faith exam process already in place before the first injection
- 2-3 hours of physician time to review and sign the draft
- A renewal calendar — most standing orders expire annually
The steps
1. Confirm your collaborating physician covers weight loss specifically
Many collaborating physician agreements are written for Botox, filler, and laser only. If yours doesn't name semaglutide, tirzepatide, or GLP-1 injectables as a covered service, the standing order you draft on top of it isn't enforceable.
Pull the agreement and check the scope-of-practice section line by line before you write anything else. If it's silent on weight loss, how to structure a collaborating physician agreement walks through adding a service-specific addendum instead of renegotiating the whole contract.
Common mistake: assuming Botox coverage extends automatically to injectable weight loss drugs. It doesn't in most states.
2. Build the dosing protocol from a verified clinical source
Your standing order needs exact starting doses, titration intervals, and maximum doses — not "per manufacturer guidelines" as a placeholder. For semaglutide, that typically means a 0.25 mg starting dose stepped up every 4 weeks; for tirzepatide, a 2.5 mg start with similar 4-week increments.
Write these as hard numbers in the document itself, sourced from the FDA label or your compounding pharmacy's certificate of analysis. Boards reject standing orders that reference an external document instead of stating the protocol directly.
Expected outcome: a one-page dosing table your NP can follow without calling the physician for routine titration.
3. Write explicit exclusion and escalation criteria
List every condition that disqualifies a patient or triggers a physician call before dosing: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, active gallbladder disease, pregnancy or breastfeeding, and prior pancreatitis.
This section is what a board investigator reads first after an adverse event. Vague language like "use clinical judgment" doesn't count as a standing order — it counts as unsupervised practice.
Common mistake: copying exclusion criteria from a general aesthetics standing order instead of writing GLP-1-specific ones.
4. Set the supervision and communication cadence
Define exactly how often the collaborating physician reviews charts for weight loss patients — weekly, biweekly, or monthly — and how escalations get communicated (phone, secure messaging, in-person). Many states set a minimum chart review frequency for this service line separately from general aesthetics.
Check your state's supervision ratio rules before finalizing this section; how to meet supervision ratio rules for collaborating physicians breaks down what most states require for weight loss specifically versus injectables generally.
5. Get the good faith exam sequence right
A good faith exam has to happen before the first dose is given, not after — and for weight loss injectables it needs to cover BMI, comorbidities, and medication history, not just a general aesthetic screening. Build this into the standing order as a hard gate: no exam on file, no first injection.
How to document good faith exams for tirzepatide patients covers the specific fields boards look for in 2026 audits.
Expected outcome: every new patient chart shows a dated, signed exam before the first dose is logged.
6. Route the draft through physician review and signature
A standing order isn't valid until the collaborating physician actually signs and dates it — not a verbal approval, not an email thread. Set a hard deadline for physician sign-off before any patient is scheduled under the new protocol.
Common mistake: starting patients on the protocol while the signature is "pending." That gap is exactly what an inspector looks for.
7. Set a renewal date and calendar reminder
Most standing orders need annual renewal, and some states require review any time the underlying drug protocol changes — which happened multiple times between 2023 and 2026 as tirzepatide dosing guidance evolved. Put the renewal date directly on the document, not in a separate tracker that gets forgotten.
Get your standing orders reviewed before launch
US Medical Directors builds and signs off on state-specific weight loss injectable protocols.
Troubleshooting
Problem: The physician won't sign off on the dosing table.
The protocol is usually too generic or missing a citation. Pull the exact FDA prescribing information or compounding pharmacy documentation and attach it as a reference exhibit.
Problem: A patient had an adverse reaction and the standing order doesn't address it.
Add an incident-specific addendum immediately, get it signed, and document the change date. Don't wait for the annual renewal cycle to fix a known gap.
Problem: Your state changed supervision rules mid-year.
Re-check the collaborating physician agreement scope and the standing order's ratio language together — a rule change often invalidates both documents at once, not just one.
Problem: Multiple locations are using different versions of the same standing order.
Centralize the document with version control and a single renewal date across locations; medical director oversight for medspa franchise groups covers how multi-location groups keep protocols consistent.
Problem: You're not sure the good faith exam sequence matches the standing order's gate.
Cross-check both documents side by side — the exam requirements listed in the standing order need to match exactly what your intake staff is actually collecting.
Tools and resources
- FDA prescribing information for the specific GLP-1 drug in use
- Your state's nurse practice act or medical practice act, current for 2026
- Chart review services for tirzepatide weight loss clinics for ongoing compliance checks after launch
- A signed collaborating physician agreement naming weight loss services explicitly
What to do next
Once the standing order is signed and live, the next compliance gap most practices hit is chart documentation — inspectors want to see that every deviation from the protocol was logged and reviewed. How to document chart reviews for medical director compliance covers the exact fields to track so the standing order and the chart history match up during an audit.
FAQ
What is a standing order for weight loss injectables?
A standing order is a physician-signed protocol that authorizes an NP, PA, or RN to administer weight loss drugs like semaglutide or tirzepatide within defined dosing and exclusion parameters, without a physician signature on each individual patient. It has to name the specific drugs, dosing schedule, and escalation triggers to be valid in 2026.
Do standing orders for weight loss injectables expire?
Most states require annual renewal, and any change to the underlying dosing protocol should trigger a review even before the renewal date. Put the expiration date directly on the document so it doesn’t get missed.
Can a nurse practitioner write their own standing order?
No — a standing order has to be signed by a supervising or collaborating physician, not the NP administering it. The NP can draft the protocol, but physician sign-off is what makes it legally enforceable.
Is a standing order the same as a collaborating physician agreement?
No, they’re separate documents that work together. The collaborating physician agreement defines the overall supervisory relationship and scope of practice; the standing order is the specific clinical protocol for one service line, like weight loss injectables.
How often should a collaborating physician review weight loss injectable charts?
Cadence depends on state rules, but weekly to monthly chart review is common for GLP-1 weight loss programs given the titration schedule and adverse event risk. Check your state’s supervision ratio requirements for the exact minimum.
What happens if a standing order is missing exclusion criteria?
A standing order without explicit exclusion criteria for conditions like MEN2 syndrome or pancreatitis history is treated as incomplete by most state boards, and any adverse event under that protocol becomes a liability exposure for both the physician and the practice.
Does a good faith exam need to happen before the standing order applies?
Yes — the good faith exam has to be completed and documented before the first dose is given under the standing order. Build this as a hard gate in the document itself, not a separate policy.
One last thing
The standing order isn't the document that gets checked most often — the chart notes proving you followed it are. A perfectly written protocol with sloppy documentation behind it fails the same audit a solid protocol with clean charting would pass in 2026.
Related guides
- How to draft standing orders for aesthetic nurse practitioners
- Good faith exams for semaglutide clinics
- Chart review services for weight loss clinics
- Collaborating physician for weight loss clinics
